7月23日，民银资本盘中下跌16.52%，报3.8港元/股，成交额1.17亿港元。该股于7月21日因保荐项目普祺医药IPO招股书失效叠加南向资金持续流出大跌17.3%，7月22日虽出现超跌反弹，但未能延续涨势，今日再度大幅走低。
消息面上，普祺医药港股招股书于7月21日正式失效，民银资本为联席保荐人之一。此前公司年度利润增长197.73%主因证券承销及保荐费收入大幅增加，保荐项目未能推进引发市场对其核心业务收入持续性的担忧。此外，近期南向资金连续多日减持该股，主力资金呈大幅净流出态势，短期抛压依然较重，前日反弹未能有效扭转资金离场趋势。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.